RPG Life Sciences Limited
NSE: RPGLIFE · Pharmaceuticals
Snapshot
Unlock RPG Life Sciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
RPG Life Sciences Limited is an integrated pharmaceutical company that develops, manufactures, and markets branded formulations, generics, and synthetic active pharmaceutical ingredients (APIs). The company operates across diverse therapeutic categories, including nephrology, oncology, and immunosuppressants, serving both domestic and international markets.
Business Model
The company generates revenue through the sale of finished dosage formulations and synthetic APIs, leveraging its manufacturing capabilities to serve various medical specialties. It operates as a subsidiary of Nucleus Life Trust and maintains a broad portfolio of therapeutic products.
Growth Outlook
Growth is driven by the expansion of its branded formulations portfolio and the continued development of synthetic APIs for global markets. The company focuses on high-growth therapeutic areas such as nephrology and rheumatology to sustain its market position.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations from bodies like the CDSCO and international health authorities.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can impact profit margins.
- Competitive Pressure. The company faces intense competition from both domestic and multinational pharmaceutical firms in the branded and generic segments.
- Currency Risk. As an exporter of APIs and formulations, the company is exposed to foreign exchange rate fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on RPG Life Sciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹734 Cr
TTM · standalone
NET PROFIT
₹119 Cr
TTM · standalone
EPS
₹72.23
TTM · standalone
RETURN ON EQUITY
21.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
27.6%
TTM · standalone
P/E
37.7x
Q1 FY27 · standalone
EV/EBITDA
24.5x
Q1 FY27 · standalone
EBITDA MARGIN
24.5%
TTM · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
RPG Life Sciences LimitedRPGLIFE | ₹4,501 Cr | 37.68 | 24.51 | 11.8% | 24.5% | 21.0% | 27.6% | +14.7% |
Orchid Pharma LimitedORCHPHARMA | ₹4,842 Cr | 592.95 | 78.06 | 10.8% | 7.1% | 0.7% | 1.5% | +32.3% |
Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,482 Cr | 155.81 | 54.77 | 17.5% | 48.8% | 18.2% | 19.8% | +7.9% |
Gufic Biosciences LimitedGUFICBIO | ₹4,462 Cr | 60.78 | 28.68 | 16.7% | 17.0% | 11.6% | 16.9% | +22.1% |
Novartis IndiaNOVARTIND | ₹4,066 Cr | 43.62 | 30.20 | -0.5% | 37.5% | 11.7% | 16.1% | +76.7% |
Aarti Drugs LimitedAARTIDRUGS | ₹3,940 Cr | 20.62 | 13.41 | — | 12.6% | 13.1% | 14.5% | -9.0% |
As of Q1 FY27
Financials
RPG Life Sciences Limited
NSE: RPGLIFE · Pharmaceuticals
Snapshot
Unlock RPG Life Sciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
RPG Life Sciences Limited is an integrated pharmaceutical company that develops, manufactures, and markets branded formulations, generics, and synthetic active pharmaceutical ingredients (APIs). The company operates across diverse therapeutic categories, including nephrology, oncology, and immunosuppressants, serving both domestic and international markets.
Business Model
The company generates revenue through the sale of finished dosage formulations and synthetic APIs, leveraging its manufacturing capabilities to serve various medical specialties. It operates as a subsidiary of Nucleus Life Trust and maintains a broad portfolio of therapeutic products.
Growth Outlook
Growth is driven by the expansion of its branded formulations portfolio and the continued development of synthetic APIs for global markets. The company focuses on high-growth therapeutic areas such as nephrology and rheumatology to sustain its market position.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations from bodies like the CDSCO and international health authorities.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can impact profit margins.
- Competitive Pressure. The company faces intense competition from both domestic and multinational pharmaceutical firms in the branded and generic segments.
- Currency Risk. As an exporter of APIs and formulations, the company is exposed to foreign exchange rate fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on RPG Life Sciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹734 Cr
TTM · standalone
NET PROFIT
₹119 Cr
TTM · standalone
EPS
₹72.23
TTM · standalone
RETURN ON EQUITY
21.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
27.6%
TTM · standalone
P/E
37.7x
Q1 FY27 · standalone
EV/EBITDA
24.5x
Q1 FY27 · standalone
EBITDA MARGIN
24.5%
TTM · standalone
Peers · Pharmaceuticals
As of Q1 FY27